WednesdayMar 27, 2019 9:00 am

Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy

BioMedWire Editorial Coverage: Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer. Gene therapies are being developed to more effectively target the treatment of cancer. Non-small cell lung cancer (NCSLC) is the leading cause of cancer death. Genprex Inc. is advancing Oncoprex, shown to benefit lung cancer patients in early trials. A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is working to…

Continue Reading

MondayMar 25, 2019 11:18 am

Genprex Inc. (NASDAQ: GNPX) is “One to Watch”

Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel therapeutic standards. Genprex holds a portfolio of 30 issued and two pending patents covering technologies and targeted molecular therapies, all exclusively licensed from University of Texas MD Anderson Cancer Center. Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who otherwise would not benefit from these important…

Continue Reading

TuesdayMar 19, 2019 6:00 pm

Genprex Inc. (NASDAQ: GNPX) Attends 31st Annual ROTH Conference

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company developing a ground-breaking approach to battling cancer based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Genprex’s Oncoprex has a multimodal mechanism ofaction whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the…

Continue Reading

FridayMar 15, 2019 12:40 pm

Genprex Inc. (NASDAQ: GNPX) Employs Trademarked Gene Therapy in Team-up to Fight Lung Cancer

Lung cancer is one of the most commonly occurring tumors in men and women, and it is the common cancer that’s most likely to result in death among all U.S. populations Genprex is advancing its trademarked Oncoprex immunogene therapy as a means of bolstering the body’s protein defenses against lung tumor growth Clinical trials for Oncoprex are evaluating ways to team it with other targeted therapies and immunotherapies to increase the overall efficacy of the therapies The war on deadly cancers continues to advance innovative developments in the field of targeted therapies that block the growth of cancer cells by…

Continue Reading

TuesdayMar 12, 2019 9:00 am

Making Profits, Saving Lives with Gene Therapy

BioMedWire Editorial Coverage: After thirty years of development, gene therapy is seeing a surge of progress and profitability. Gene therapies tackle diseases by altering the genetic makeup of patients’ cells. Recent mergers and research developments make this a promising time to invest in the sector. Gene therapy companies are developing treatments for everything from cancer and HIV to skin diseases. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is developing treatments to tackle lung cancer. Spark Therapeutics Inc. (NASDAQ: ONCE), which recently entered a merger agreement with the Roche Group, targets ailments such as retinal and neurodegenerative diseases. Dyadic International Inc. (OTCQX:…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050